When using nanodevices in oncology, it is necessary to provide the efficiency of the performance of these nanodevices simultaneously with their safety for an organism. These are conflicting objectives to some extent. Nevertheless, as shown in this work, an approach that helps to eliminate this contradiction is offered. For recognition and destruction of cancer cells in vivo it is suggested to use instead of one type simultaneously two types of introduced into an organism specialized nanodevices interacting with each other. Some of the nanodevices only recognize cancer cells, while the other ones, that can not recognize them, find cells being marked by nanodevices of the first type, and destroy them. This makes possible to increase the reliability of the cancer cell recognition process on the one side, and have the process of their destruction rather safe for an organism on the other side.

Download full-text PDF

Source

Publication Analysis

Top Keywords

cancer cells
8
nanodevices
5
[on possibility
4
possibility improving
4
improving efficiency
4
cancer
4
efficiency cancer
4
cancer recognition
4
recognition eradication
4
eradication vivo
4

Similar Publications

EZH2 inhibition induces pyroptosis via RHA-mediated S100A9 overexpression in myelodysplastic syndromes.

Exp Hematol Oncol

January 2025

Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Myelodysplastic Syndromes (MDS) represent a group of heterogeneous myeloid clonal diseases derived from aberrant hematopoietic stem/progenitor cells. Enhancer of zeste homolog 2 (EZH2) is an important regulator in gene expression through methyltransferase-dependent or methyltransferase-independent mechanisms. Herein, we found EZH2 inhibition led to MDS cell pyroptosis through RNA Helicase A (RHA) down-regulation induced overexpression of S100A9, a key regulator of inflammasome activation and pyroptosis.

View Article and Find Full Text PDF

Detection of early relapse in multiple myeloma patients.

Cell Div

January 2025

Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Background: Multiple myeloma (MM) represents the second most common hematological malignancy characterized by the infiltration of the bone marrow by plasma cells that produce monoclonal immunoglobulin. While the quality and length of life of MM patients have significantly increased, MM remains a hard-to-treat disease; almost all patients relapse. As MM is highly heterogenous, patients relapse at different times.

View Article and Find Full Text PDF

Background: Dishevelled-associated activator of morphogenesis1 (DAAM1) is a member of the evolutionarily conserved Formin family and plays a significant role in the malignant progression of various human cancers. This study aims to explore the clinical and biological significance of DAAM1 in pancreatic cancer.

Methods: Multiple public datasets and an in-house cohort were utilized to assess the clinical relevance of DAAM1 in pancreatic cancer.

View Article and Find Full Text PDF

With the progress of atherosclerosis (AS), the arterial lumen stenosis and compact plaque structure, the thickening intima and the narrow gaps between endothelial cells significantly limit the penetration efficiency of nanoprobe to plaque, weakening the imaging sensitivity and therapy efficiency. Thus, in this study, a HO-NIR dual-mode nanomotor, Gd-doped mesoporous carbon nanoparticles/Pt with rapamycin (RAPA) loading and AntiCD36 modification (Gd-MCNs/Pt-RAPA-AC) was constructed. The asymmetric deposition of Pt on Gd-MCNs catalyzed HO at the inflammatory site to produce O, which could promote the self-motion of the nanomotor and ease inflammation microenvironment of AS plaque.

View Article and Find Full Text PDF

Prominosomes - a particular class of extracellular vesicles containing prominin-1/CD133?

J Nanobiotechnology

January 2025

Biotechnology Center (BIOTEC) and Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Tatzberg 47-49, 01307, Dresden, Germany.

Extracellular membrane vesicles (EVs) offer promising values in various medical fields, e.g., as biomarkers in liquid biopsies or as native (or bioengineered) biological nanocarriers in tissue engineering, regenerative medicine and cancer therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!